EGFR and lung adenocarcinoma: Similarly, in epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma, a TKI, osimertinib, demonstrated remarkable efficacy in patients with LMD, achieving a durable clinical response up to one year in the BLOOM study [18].